San Diego, CA, United States
San Diego, CA, United States

Halozyme Therapeutics, based in San Diego, California, is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. http://www.halozyme.com Wikipedia.


Time filter

Source Type

SAN DIEGO, Nov. 10, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), an oncology biotech developing novel oncology and drug-delivery therapies, and Genentech, a member of the Roche Group, today announced an agreement to collaborate on clinical studies evaluating up to...


News Article | November 23, 2016
Site: www.biosciencetechnology.com

San Diego-based biotech company Halozyme Therapeutics Inc., has announced a partnership with Genentech, a member of the Roche group, to perform two clinical studies evaluate its investigational drug in up to eight tumor types. Halozyme president and CEO, Dr. Helen Torley, told Bioscience Technology that the trials are still being developed but there will be two basket studies.  The first, is a phase 1b/2 study led by Genentech, to evaluate their anti-PDL1 immunotherapy Tecentriq (atezolizumab), with Halozyme’s investigational drug PEGPH20 in six tumor types, starting with pancreatic and gastric cancer patients. Haloyzyme will lead the second study to investigate Tecentriq, PEGPH20 and chemotherapy in patients with advanced gallbladder and billary cancers. PEGPH2 is an enzyme that targets and degrades hyaluronan, or HA, in the tumor microenvironment.  Torley said that HA is a glycosaminoglycan – or a chain of natural sugars distributed throughout human tissue that can accumulate in higher concentrations around certain cancer cells, potentially limiting the access of cancer therapies. “By degrading HA with PEGPH20 in preclinical models, we have measured higher concentrations of therapeutic agents or the body’s natural immune cells reaching the targeted tumor,” Torley said. The hope is that by combining PEGPH20 and Genentech’s anti-PDL1 checkpoint inhibitor, more of the therapy will be able to reach patients’ tumors. The studies will begin in 2017.


News Article | November 7, 2016
Site: www.prnewswire.com

SAN DIEGO, Nov. 7, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results and recent highlights for the third quarter ended September 30. "The third quarter was highlighted by Genentech's BLA filing for rituximab in a subcutaneous formulation...


— Bile Duct Cancer (Cholangiocarcinoma) - Companies Involved in Therapeutics Development are 4SC AG, Adgero Biopharmaceuticals Inc, Agios Pharmaceuticals Inc, Ariad Pharmaceuticals Inc, ArQule Inc, Array BioPharma Inc, Arrien Pharmaceuticals LLC, Aslan Pharmaceuticals Pte Ltd, Bavarian Nordic A/S, Bayer AG, BeiGene Ltd, Blueprint Medicines Corp, Boehringer Ingelheim GmbH, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corp, CellAct Pharma GmbH, Cellceutix Corp, Cellular Biomedicine Group Inc, Concordia International Corp, Cornerstone Pharmaceuticals Inc, Daiichi Sankyo Company Ltd, Delcath Systems Inc, Eisai Co Ltd, Eli Lilly and Company, Exelixis Inc, F. Hoffmann-La Roche Ltd, H3 Biomedicine Inc, Halozyme Therapeutics Inc, Hutchison MediPharma Ltd, Incyte Corp, Innopharmax Inc, INSYS Therapeutics Inc, Johnson & Johnson, Komipharm International Co Ltd, Loxo Oncology, Inc., Mebiopharm Co Ltd, MedImmune LLC, Merck & Co Inc, NanoCarrier Co Ltd, NormOxys Inc, Novartis AG, NuCana BioMed Ltd, Oasmia Pharmaceutical AB, OncoTherapy Science Inc, Ono Pharmaceutical Co Ltd, Panacea Pharmaceuticals Inc, PCI Biotech Holding ASA, Pfizer Inc, Pharma Mar SA, Provecs Medical GmbH, Puma Biotechnology Inc, RedHill Biopharma Ltd, Sanofi, Senhwa Biosciences Inc, Shanghai Pharmaceutical Co Ltd, Sun Pharma Advanced Research Company Ltd, SynCore Biotechnology Co Ltd, SyntheX Inc, Taiwan Liposome Company Ltd, tella Inc, Threshold Pharmaceuticals Inc and VasGene Therapeutics Inc. Bile duct cancer or cholangiocarcinoma are tumors that occur in the bile duct. Symptoms include discomfort in the tummy area (abdomen), loss of appetite, high temperatures (fevers) and weight loss. Treatment includes chemotherapy and radiation therapy. The Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 49, 18, 10 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 4 molecules, respectively. Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Inquire more about this report at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=786901 Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. • The pipeline guide provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma) (Oncology). • The pipeline guide reviews pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Bile Duct Cancer (Cholangiocarcinoma) (Oncology) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Bile Duct Cancer (Cholangiocarcinoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) (Oncology) • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. • Find and recognize significant and varied types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) (Oncology). • Classify potential new clients or partners in the target demographic. • Develop tactical initiatives by understanding the focus areas of leading companies. • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. • Formulate corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline depth and focus of Indication therapeutics. • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. For more information, please visit http://www.reportsnreports.com/reports/786901-bile-duct-cancer-cholangiocarcinoma-pipeline-review-h2-2016.html


News Article | February 23, 2017
Site: www.prnewswire.com

SAN DIEGO, Feb. 23, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will be presenting at the Cowen & Company 37th Annual Healthcare Conference in Boston on Tuesday, March 7 at 11:20 a.m....


News Article | February 28, 2017
Site: www.prnewswire.com

SAN DIEGO, Feb. 28, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results and recent highlights for the fourth quarter and full year ended December 31, 2016. "We...


News Article | December 28, 2016
Site: www.prweb.com

The key to solving the glycosylation puzzle stands with N‐glycosylation analysis of a development‐phase glycoprotein, having multiple glycosylation sites using these orthogonal methods demonstrated that complementarity. Most structures were simply identified by public database search either by Expasy or GUcal, based on their molecular weight or measured glucose unit values. Glycan structures not included in the GuCal database were deciphered by exoglycosidase‐based glycan sequencing, to sequentially remove the sugar residues from the nonreductive end of the glycan structures. In this presentation, attendees can expect a compelling discussion on the complementarity of various liquid phase bioseparation methods including capillary electrophoresis and liquid chromatography. Participants will learn how to separate and identify N-Glycans in minutes and compare liquid phase separation methods for N-Glycan analysis. They will also receive an introduction to the new Fast Glycan Labeling & Analysis Kit from SCIEX, along with 60-minute sample prep for up to 96 glycan samples. The speaker for this webinar will be Laura Salmeron, associate director analytical testing support at Halozyme Therapeutics Inc. As an industry veteran, Salmeron has more than 25 years of experience working in the clinical and biotechnology field supporting protein therapeutics. She earned her Bachelor in Science in biochemistry and microbiology and medical technologist from the University Autonoma of Guadalajara, Mexico. In 2015 Laura joined Halozyme Therapeutics in San Diego CA, working with Halozyme Enhance platform partners and leading the Potency group and as a key member of the Analytical Development team working with FIH, Clinical and Commercial products supporting method transfers at CRO’s and CMO’s and regulatory submissions. The free webinar will be hosted by LabRoots February 1, 2017, beginning at 8 a.m. PT, 11 a.m. ET. To read more on this event, learn about P.A.C.E. and Florida continuing education credits, or to register, click here. About SCIEX SCIEX helps to improve the world we live in by enabling scientists and laboratory analysts to find answers to the complex analytical challenges they face. The company's global leadership and world-class service and support in the capillary electrophoresis and liquid chromatography-mass spectrometry industry have made it a trusted partner to thousands of the scientists and lab analysts worldwide who are focused on basic research, drug discovery and development, food and environmental testing, forensics and clinical research. With over 40 years of proven innovation, SCIEX excels by listening to and understanding the ever-evolving needs of its customers to develop reliable, sensitive and intuitive solutions that continue to redefine what is achievable in routine and complex analysis. For more information, please visit sciex.com. About LabRoots LabRoots is the leading scientific social networking website and producer of educational virtual events and webinars. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning, and is a primary source for current scientific news, webinars, virtual conferences, and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.


News Article | November 21, 2016
Site: www.prnewswire.com

SAN DIEGO, Nov. 21, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that AbbVie has discontinued a development program using the Halozyme ENHANZE™ platform technology and the tumor necrosis factor alpha (TNF-alpha) target following completion of a phase 1...


NEW YORK, March 2, 2017 /PRNewswire/ -- In today's pre-market research, Stock-Callers.com presents these Biotech equities for review: Halozyme Therapeutics Inc. (NASDAQ: HALO), CytRx Corp. (NASDAQ: CYTR), Cara Therapeutics Inc. (NASDAQ: CARA), and Keryx Biopharmaceuticals Inc....


News Article | December 22, 2016
Site: www.prnewswire.com

SAN DIEGO, Dec. 22, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will be presenting at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco on Mon., Jan. 9 at 3:00 p.m. PT /...

Loading Halozyme Therapeutics collaborators
Loading Halozyme Therapeutics collaborators